Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 2b Study to Evaluate the Safety and Efficacy of Elagolix in Premenopausal Women With Heavy Menstrual Bleeding Associated With Uterine Fibroids

Trial Profile

A Phase 2b Study to Evaluate the Safety and Efficacy of Elagolix in Premenopausal Women With Heavy Menstrual Bleeding Associated With Uterine Fibroids

Completed
Phase of Trial: Phase II

Latest Information Update: 10 Oct 2018

At a glance

  • Drugs Elagolix (Primary) ; Estradiol/norethisterone (Primary)
  • Indications Uterine leiomyoma
  • Focus Therapeutic Use
  • Sponsors AbbVie
  • Most Recent Events

    • 10 Oct 2018 Results of a subgroup analysis assessing eficacy and safety of elagolix in a subgroup of women with both UF and adenomyosis, presented at the American Society for Reproductive Medicine Scientific Congress 2018.
    • 05 Oct 2018 Results published in the Obstetrics and Gynecology
    • 23 May 2018 Results asessing effect of elagolox on quality of life presented at the 23rd Annual International Meeting of the International Society for Pharmacoeconomics and Outcomes Research.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top